This Frost & Sullivan research service titled InvestFrost Healthcare - European Insulin Delivery Devices Market Outlook provides comprehensive investment themes and growth indices for the market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: insulin syringes, insulin pens, insulin pumps and needle-free injection techniques.
Market Overview
High Prevalence of Diabetes in Europe Drives the Insulin Delivery Devices Market
Europe has one of the highest prevailing rates of diabetes that are doubling every year, making it a profitable investment venue for the insulin delivery devices market. Insulin pens are the fastest-growing segment of the insulin delivery devices market as it is convenient and more insurance companies are beginning to pay for the devices. Europe has one of the highest acceptance levels of insulin pens. Their popularity will continue due to the easy availability of insurance reimbursements. “A significant area driving growth in this market is the high level of compatibility of insulin pens with the fast-paced, modern environment,” says the analyst of this research. “Considering the preference for, and level of acceptance of insulin pens in the European healthcare environment, companies present in this segment stand to make the strongest gains.”
Europe will be a profitable investment destination due to the percent of clinically obese people and the region’s greying demographic. Although it is one of the largest markets for medical devices, many countries such as the United Kingdom are unable to keep up with the rising healthcare needs. The vast majority of insulin users in Europe prefer pen devices to administer insulin, unlike in the United States, where insulin pumps and syringes have a higher market share.
The huge untapped potential in this market could be met by conducting awareness campaigns to increase the frequency of tests. Possibly the most effective method for the dissemination of insulin to diabetic patients will be the cooperation of insulin (pharmaceutical) producers and insulin delivery device suppliers. “Cooperative agreements and projects will help both medical device and pharmaceutical companies benefit from mutual synergies,” concludes the analyst. “Such an approach would enable both sides to realise savings on additional capital investment and the operation costs of extending their product portfolios.”
(0 items)
